R1 RCM Inc. provides revenue cycle management (RCM) for healthcare providers in the United States. It offers end-to-end RCM services to manage their revenue cycle operations, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, and bill preparation and collection from patients and payers. The company also provides modular services comprising physician advisory services, which assists hospitals in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; and revenue capture services, including charge capture, charge description master maintenance, and pricing services. It serves single or multi-hospital healthcare systems, and their respective affiliated ambulatory clinics and physician practice groups. The company was formerly known as Accretive Health, Inc. and changed its name to R1 RCM Inc. in January 2017. R1 RCM Inc. was founded in 2003 and is headquartered in Chicago, Illinois.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Management services
Sub-IndustryHealth Care Services
SectorFinance
SymbolNASDAQ:RCM
CUSIP00438V10
Phone312-324-7820
Debt
Debt-to-Equity Ratio15.78
Current Ratio1.08
Quick Ratio1.08
Price-To-Earnings
Trailing P/E Ratio-19.84
Forward P/E Ratio-51.35
P/E GrowthN/A
Sales & Book Value
Annual Sales$449.80 million
Price / Sales2.13
Cash FlowN/A
Price / CashN/A
Book Value$0.32 per share
Price / Book27.28
Profitability
EPS (Most Recent Fiscal Year)($0.44)
Net Income$-58,800,000.00
Net Margins-11.31%
Return on Equity-52.71%
Return on Assets-4.63%
Miscellaneous
Employees9,965
Outstanding Shares109,980,000
Market Cap$943.65 million
R1 RCM (NASDAQ:RCM) Frequently Asked Questions
What is R1 RCM's stock symbol?
R1 RCM trades on the NASDAQ under the ticker symbol "RCM."
How were R1 RCM's earnings last quarter?
R1 RCM Inc (NASDAQ:RCM) announced its earnings results on Thursday, August, 9th. The financial services provider reported ($0.07) EPS for the quarter, missing the Zacks' consensus estimate of ($0.05) by $0.02. The financial services provider earned $207.90 million during the quarter, compared to the consensus estimate of $200.59 million. R1 RCM had a negative return on equity of 52.71% and a negative net margin of 11.31%. The company's revenue was up 109.2% compared to the same quarter last year. View R1 RCM's Earnings History.
When is R1 RCM's next earnings date?
What price target have analysts set for RCM?
4 brokerages have issued 1-year target prices for R1 RCM's shares. Their forecasts range from $9.00 to $17.00. On average, they anticipate R1 RCM's share price to reach $11.75 in the next twelve months. This suggests a possible upside of 34.6% from the stock's current price. View Analyst Price Targets for R1 RCM.
What is the consensus analysts' recommendation for R1 RCM?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for R1 RCM.
What are Wall Street analysts saying about R1 RCM stock?
Here are some recent quotes from research analysts about R1 RCM stock:
- 1. According to Zacks Investment Research, "R1 RCM Inc. offers financial services for the health care industries. The Company provides revenue cycle management and physician advisory services, as well as transforms and manages the commercial infrastructure of health care organizations. R1 RCM Inc., formerly known as Accretive Health, Inc., is headquartered in Chicago, Illinois. " (10/10/2018)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating on R1 RCM shares and maintain our 12-month price target of $10. We have adjusted our quarterly estimates to reflect additional expenses in 2Q18 relating to onboarding of new contracts. We have increased our 4Q18 estimates to offset the change in 2Q18. Our full year adjusted EBITDA estimate remains virtually unchanged at $53.5 million. 2020 estimates are unchanged as well. The company’s 2018 adjusted EBITDA guidance is $50-55 million. Our previous estimates simply did not properly reflect the likely ramp throughout the course of the year. The company is scheduled to report 2Q18 results on the market open." (7/27/2018)
Who are some of R1 RCM's key competitors?
Who are R1 RCM's key executives?
R1 RCM's management team includes the folowing people:
- Mr. Joseph Gerard Flanagan, Pres, CEO & Director (Age 47)
- Mr. Christopher Simon Ricaurte, CFO & Treasurer (Age 58)
- Mr. Gary S. Long, Exec. VP & Chief Commercial Officer (Age 48)
- Mr. Richard B. Evans Jr., Principal Accounting Officer, Sr. VP & Corp. Controller (Age 50)
- Mr. Atif A. Rahim, Sr. VP of Investor Relations & Bus. Devel.
Who are R1 RCM's major shareholders?
Which institutional investors are selling R1 RCM stock?
How do I buy shares of R1 RCM?
Shares of RCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is R1 RCM's stock price today?
One share of RCM stock can currently be purchased for approximately $8.73.
How big of a company is R1 RCM?
R1 RCM has a market capitalization of $943.65 million and generates $449.80 million in revenue each year. The financial services provider earns $-58,800,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. R1 RCM employs 9,965 workers across the globe.
What is R1 RCM's official website?
How can I contact R1 RCM?
R1 RCM's mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The financial services provider can be reached via phone at 312-324-7820 or via email at arahim@r1rcm.com.
MarketBeat Community Rating for R1 RCM (NASDAQ RCM)
MarketBeat's community ratings are surveys of what our community members think about R1 RCM and other stocks. Vote "Outperform" if you believe RCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
